Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023

ワクチンの世界市場予測(~2023年):生ワクチン、トキソイドワクチン、組換えワクチン

◆タイトル:Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023
◆商品コード:PH-6528
◆調査・発行会社:MarketsandMarkets
◆発行日:2018年8月14日
◆ページ数:185
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、ワクチンの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、技術別(生ワクチン、トキソイドワクチン、組換えワクチン)分析、疾患別(肺炎球菌、インフルエンザ、DTP、HPV、肝炎、髄膜炎菌、ロタウイルス、ポリオ、MMR、水痘、デング熱)分析、投与経路別(IM・SC、経口)分析、患者別(小児、成人) 分析、ワクチンの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. Factors such as rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing company initiatives to enhance R&D are driving the vaccines market.
This report segments the vaccines market into technology, type, disease indication, route of administration, patient type, and region. Based on technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate vaccines segment is expected to account for the largest share of the vaccines market, in 2018. Rising prevalence of diseases and increasing government initiatives are the key factors driving the growth of this segment.

Based on the type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent vaccines segment is projected to register the highest CAGR during the forecast period. Rising prevalence of diseases and increasing government and nongovernment initiatives to promote immunization are the key factors driving the growth of this segment.

Based on disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, dengue, and other disease indications. The meningococcal disease segment is expected to witness the highest growth during the forecast period. The growth of this segment is primarily attributed to high incidence of meningococcal disease and increasing government investments in meningococcal vaccination programs.

Based on route of administration, the vaccines market is segmented into intramuscular and subcutaneous administration, oral administration, and other routes of administration. The intramuscular and subcutaneous administration segment is expected to hold the largest share of the vaccines market, in 2018. The growth of this segment is attributed to benefits associated with this mode of administration such as faster absorption of medication in blood, and lower rate of injection site reactions.

Based on the patient type, the vaccines market is segmented into pediatrics and adults. The adult segment is expected to register the highest CAGR during the forecast period. Factors like the increasing investments by companies for the development of new adult vaccines and government initiatives for immunization are driving the growth of this segment.

Vaccine Market

In 2018, North America is expected to dominate the market, followed by Europe. The high growth of the North American market is attributed to the factors such as increasing investments by government organizations and companies to promote immunization as well as develop new vaccines.

While North America is expected to dominate the market in 2018, Asia is expected to register the highest CAGR during the forecast period. The high growth in this market is attributed to increasing investments by companies in the emerging economies such as India and China and rising disposable income.

While the vaccines market presents significant growth opportunities, market growth may be hindered due to the high cost of vaccine development. The vaccines market is highly competitive with several big and small players. Prominent players in the vaccines market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), GlaxoSmithKline, plc (UK), Johnson & Johnson (US), MedImmune, LLC (US), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi Pasteur SA (France), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Biological E (India), and Panacea Biotec (India).

【レポートの目次】

1 Introduction (Page No. – 18)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 22)
2.1 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 31)

4 Premium Insights (Page No. – 35)
4.1 Overview of the Vaccines Market
4.2 Vaccines Market, By Type, 2018–2023
4.3 Vaccines Market, By End User, 2018 vs 2023 (USD Billion)
4.4 Geographic Analysis: Vaccines Market, By Technology
4.5 Vaccines Market, By Route of Administration, 2018 vs 2023 (USD Billion)
4.6 Geographical Snapshot of the Vaccines Market

5 Market Overview (Page No. – 39)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Infectious Diseases
5.2.1.2 Rising Focus on Immunization Programs
5.2.1.3 Growing Government Support for Vaccine Development
5.2.1.4 Increasing Company Initiatives to Enhance Vaccine R&D
5.2.2 Restraints
5.2.2.1 High Cost of Vaccine Development
5.2.3 Opportunities
5.2.3.1 High Growth Prospects in Emerging Markets
5.2.3.2 Focus on Therapeutic Vaccines
5.2.3.3 Use of Adjuvants in Vaccines
5.2.4 Challenges
5.2.4.1 Inadequate Access to Vaccines
5.2.4.2 Product Recalls

6 Industry Insights (Page No. – 46)
6.1 Regulatory Landscape
6.1.1 North America
6.1.2 Europe
6.1.3 Asia
6.1.4 RoW
6.2 Key Pipeline Products
6.3 New Vaccine Opportunities
6.3.1 Hiv
6.3.1.1 HIV Vaccine: Product Pipeline
6.3.1.2 HIV Vaccine: Public-Private Initiatives
6.3.1.3 HIV Vaccine: Funding
6.3.2 Malaria
6.3.2.1 Malaria Vaccine: Product Pipeline
6.3.2.2 Malaria Vaccine: Public-Private Initiatives
6.3.3 Zika
6.3.3.1 Zika Vaccine: Product Pipeline
6.3.3.2 Zika Vaccine: Public-Private Initiatives
6.3.3.3 Zika Vaccine: Funding
6.3.4 Ebola
6.3.4.1 Ebola Vaccine: Product Pipeline
6.3.4.2 Ebola Vaccine: Public-Private Initiatives
6.3.4.3 Ebola Vaccine: Funding

7 Vaccines Market, By Technology (Page No. – 57)
7.1 Introduction
7.2 Conjugate Vaccines
7.3 Inactivated and Subunit Vaccines
7.4 Live Attenuated Vaccines
7.5 Recombinant Vaccines
7.6 Toxoid Vaccines

8 Vaccines Market, By Type (Page No. – 65)
8.1 Introduction
8.2 Monovalent Vaccines
8.3 Multivalent Vaccines

9 Vaccines Market, By Disease Indication (Page No. – 70)
9.1 Introduction
9.2 Pneumococcal Disease
9.3 DTP
9.4 Influenza
9.5 HPV
9.6 Meningococcal Disease
9.7 Polio
9.8 Rotavirus
9.9 Hepatitis
9.10 MMR
9.11 Varicella
9.12 Dengue
9.13 Herpes Zoster
9.14 Other Disease Indications

10 Vaccines Market, By Route of Administration (Page No. – 87)
10.1 Introduction
10.2 Intramuscular and Subcutaneous Administration
10.3 Oral Administration
10.4 Other Routes of Administration

11 Vaccines Market, By Patient Type (Page No. – 92)
11.1 Introduction
11.2 Pediatric Patients
11.3 Adult Patients

12 Vaccines Market, By Region (Page No. – 97)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 RoE
12.4 Asia
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Rest of Asia (Roa)
12.5 Rest of the World (RoW)

13 Competitive Landscape (Page No. – 127)
13.1 Overview
13.2 Market Share Analysis
13.3 Competitive Situation and Trends
13.3.1 Agreements, Partnerships, and Collaborations
13.3.2 Product Launches and Approvals
13.3.3 Acquisitions
13.3.4 Expansions

14 Company Profiles (Page No. – 133)
(Business Overview, Products Offered, Recent Developments, MnM View)*
14.1 Pfizer
14.2 Glaxosmithkline
14.3 Merck
14.4 Sanofi Pasteur
14.5 CSL Limited
14.6 Emergent Biosolutions
14.7 Johnson & Johnson
14.8 Medimmune, LLC (A Subsidiary of Astrazeneca)
14.9 Astellas Pharma
14.10 Serum Institute of India
14.11 Bavarian Nordic
14.12 Mitsubishi Tanabe Pharma Corporation
14.13 Daiichi Sankyo Company
14.14 Panacea Biotec
14.15 Biological E

*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

15 Appendix (Page No. – 178)
15.1 Discussion Guide
15.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
15.3 Available Customizations
15.4 Related Reports
15.5 Author Details

List of Tables (93 Tables)

Table 1 Incidence of Diseases
Table 2 NIH Funding for Vaccine Research, 2013–2018 (USD Million)
Table 3 Immunization Coverage, By Disease, 2015 vs 2016
Table 4 Regulatory Authorities in Europe
Table 5 Regulatory Authorities in Asia
Table 6 Key Pipeline Vaccines
Table 7 Estimated Investments in HIV Vaccines, By Investor (2015–2016)
Table 8 Ebola Projects Funded By Ec (2014–2020)
Table 9 Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 10 Cost of Meningococcal Conjugate Vaccines
Table 11 Conjugate Vaccines Market, By Region, 2016–2023 (USD Million)
Table 12 Examples of Inactivated and Subunit Vaccines
Table 13 Inactivated and Subunit Vaccines Market, By Region, 2016–2023 (USD Million)
Table 14 Live Attenuated Vaccines Market, By Region, 2016–2023 (USD Million)
Table 15 Examples of Recombinant Vaccines
Table 16 Recombinant Vaccines Market, By Region, 2016–2023 (USD Million)
Table 17 Toxoid Vaccines Market, By Region, 2016–2023 (USD Million)
Table 18 Vaccines Market, By Type, 2016–2023 (USD Million)
Table 19 Monovalent Vaccines Market, By Region, 2016–2023 (USD Million)
Table 20 Examples of Notable Multivalent Vaccines Available in the Market
Table 21 Multivalent Vaccines Market, By Region, 2016–2023 (USD Million)
Table 22 Vaccines Market, By Disease Indication, 2016–2023 (USD Million)
Table 23 List of Commercially Available Pneumococcal Vaccines in the Market
Table 24 Vaccines Market for Pneumococcal Disease, By Region, 2016–2023 (USD Million)
Table 25 List of Commercially Available DTP Vaccines in the Market
Table 26 Vaccines Market for DTP, By Region, 2016–2023 (USD Million)
Table 27 List of Commercially Available Influenza Vaccines in the Market
Table 28 Vaccines Market for Influenza, By Region, 2016–2023 (USD Million)
Table 29 List of Commercially Available HPV Vaccines in the Market
Table 30 Vaccines Market for HPV, By Region, 2016–2023 (USD Million)
Table 31 List of Commercially Available HPV Vaccines in the Market
Table 32 Vaccines Market for Meningococcal Disease, By Region, 2016–2023 (USD Million)
Table 33 List of Commercially Available Polio Vaccines in the Market
Table 34 Vaccines Market for Polio, By Region, 2016–2023 (USD Million)
Table 35 List of Commercially Available Rotavirus Vaccines in the Market
Table 36 Vaccines Market for Rotavirus, By Region, 2016–2023 (USD Million)
Table 37 List of Commercially Available Hepatitis Vaccines in the Market
Table 38 Vaccines Market for Hepatitis, By Region, 2016–2023 (USD Million)
Table 39 List of Commercially Available MMR Vaccines in the Market
Table 40 Vaccines Market for MMR, By Region, 2016–2023 (USD Million)
Table 41 List of Commercially Available Varicella Vaccines in the Market
Table 42 Vaccines Market for Varicella, By Region, 2016–2023 (USD Million)
Table 43 Vaccines Market for Herpes Zoster, By Region, 2016–2023 (USD Million)
Table 44 List of Commercially Available Vaccines for Other Disease Indications in the Market
Table 45 Vaccines Market for Other Disease Indications, By Region, 2016–2023 (USD Million)
Table 46 Vaccines Market, By Route of Administration, 2016–2023 (USD Million)
Table 47 Vaccines Market for Intramuscular and Subcutaneous Administration, By Region, 2016–2023 (USD Million)
Table 48 Vaccines Market for Oral Administration, By Region, 2016–2023 (USD Million)
Table 49 Vaccines Market for Other Routes of Administration, By Region, 2016–2023 (USD Million)
Table 50 Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 51 Vaccines Market for Pediatric Patients, By Region, 2016–2023 (USD Million)
Table 52 North America: Vaccines Market for Pediatric Patients, By Country, 2016–2023 (USD Million)
Table 53 Vaccines Market for Adult Patients, By Region, 2016–2023 (USD Million)
Table 54 North America: Vaccines Market for Adult Patients, By Country, 2016–2023 (USD Million)
Table 55 Vaccines Market, By Region, 2016–2023 (USD Million)
Table 56 North America: Vaccines Market, By Country, 2016–2023 (USD Million)
Table 57 North America: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 58 North America: Vaccines Market, By Type, 2016–2023 (USD Million)
Table 59 North America: Vaccines Market, 2016–2023 (USD Million)
Table 60 North America: Vaccines Market, 2016–2023 (USD Million)
Table 61 North America: Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 62 US: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 63 US: Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 64 Canada: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 65 Canada: Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 66 Europe: Vaccines Market, By Country, 2016–2023 (USD Million)
Table 67 Europe: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 68 Europe: Vaccines Market, By Type, 2016–2023 (USD Million)
Table 69 Europe: Vaccines Market, By Disease Indication, 2016–2023 (USD Million)
Table 70 Europe: Vaccines Market, By Route of Administration, 2016–2023 (USD Million)
Table 71 Europe: Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 72 Germany: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 73 UK: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 74 France: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 75 Italy: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 76 Spain: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 77 RoE: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 78 Asia: Health Expenditure Per Capita, By Country, 2000, 2014 & 2016 (USD)
Table 79 Asia: Vaccines Market, By Country, 2016–2023 (USD Million)
Table 80 Asia: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 81 Asia: Vaccines Market, By Type, 2016–2023 (USD Million)
Table 82 Asia: Vaccines Market, By Disease Indication, 2016–2023 (USD Million)
Table 83 Asia: Vaccines Market, By Route of Administration, 2016–2023 (USD Million)
Table 84 Asia: Vaccines Market, By Patient Type, 2016–2023 (USD Million)
Table 85 Japan: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 86 China: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 87 India: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 88 RoA: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 89 RoW: Vaccines Market, By Technology, 2016–2023 (USD Million)
Table 90 RoW: Vaccines Market, By Type, 2016–2023 (USD Million)
Table 91 RoW: Vaccines Market, 2016–2023 (USD Million)
Table 92 RoW: Vaccines Market, 2016–2023 (USD Million)
Table 93 RoW: Vaccines Market, By Patient Type, 2016–2023 (USD Million)

List of Figures (46 Figures)

Figure 1 Vaccines Market Segmentation
Figure 2 Market Size Estimation: Bottom-Up Approach
Figure 3 Market Size Estimation: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Vaccines Market, By Technology, 2018–2023
Figure 7 Vaccines Market, By Type, 2018 vs 2023 (USD Billion)
Figure 8 Vaccines Market, By Disease Indication, 2018 vs 2023 (USD Billion)
Figure 9 Vaccines Market, By Route of Administration, 2018 vs 2023 (USD Billion)
Figure 10 Vaccines Market, By Patient Type, 2018 vs 2023 (USD Billion)
Figure 11 Geographical Snapshot of the Vaccines Market
Figure 12 High Prevalence of Diseases and Rising Focus on Immunization Programs are Driving Market Growth
Figure 13 Monovalent Vaccines Segment to Register the Highest Growth During the Forecast Period
Figure 14 Pediatrics Segment to Dominate the Vaccines Market in 2023 (USD Billion)
Figure 15 Conjugate Vaccines Segment to Hold Largest Share of the Vaccines Market in 2018
Figure 16 Intramuscular and Subcutaneous Administration Segment to Register the Highest Growth During the Forecast Period
Figure 17 US to Dominate the Vaccines Market in 2018
Figure 18 Vaccine Market: Drivers, Restraints, Opportunities, and Challenges
Figure 19 Regulatory Approval Process for Vaccines
Figure 20 R&D Funding for HIV Preventive Vaccines, By Investor, 2016
Figure 21 Conjugate Vaccines Segment to Dominate the Vaccines Market During the Forecast Period
Figure 22 Monovalent Vaccines to Grow at the Highest Rate in the Vaccines Market, By Type
Figure 23 Pneumococcal Disease Segment to Lead Vaccines Market, By Disease Indication, During 2018–2023
Figure 24 Vaccines Market for Dengue, 2016–2023 (USD Million)
Figure 25 Intramuscular and Subcutaneous Administration Segment to Account for the Vaccines Market, 2018–2023 (USD Million)
Figure 26 Pediatric Patients Segment to Account for the Largest Share of the Vaccines Market, 2018 (USD Million)
Figure 27 North America: Vaccines Market Snapshot
Figure 28 Europe: Vaccines Market Snapshot
Figure 29 Asia: Vaccines Market Snapshot
Figure 30 RoW: Vaccines Market Snapshot
Figure 31 Key Developments in the Vaccine Market From 2015 to 2018
Figure 32 Market Evolution Framework
Figure 33 Vaccines Market Share Analysis, By Key Player, 2017
Figure 34 Pfizer: Company Snapshot (2017)
Figure 35 Glaxosmithkline: Company Snapshot (2017)
Figure 36 Merck: Company Snapshot (2017)
Figure 37 Sanofi Pasteur: Company Snapshot (2017)
Figure 38 CSL Limited: Company Snapshot (2017)
Figure 39 Emergent Biosolutions: Company Snapshot (2017)
Figure 40 Johnson & Johnson: Company Snapshot (2017)
Figure 41 Astrazeneca: Company Snapshot (2017)
Figure 42 Astellas Pharma: Company Snapshot (2017)
Figure 43 Bavarian Nordic: Company Snapshot (2017)
Figure 44 Mitsubishi Tanabe Pharma Corporation: Company Snapshot (2017)
Figure 45 Daiichi Sankyo Company: Company Snapshot (2017)
Figure 46 Panacea Biotec: Company Snapshot (2017)



★調査レポート[ワクチンの世界市場予測(~2023年):生ワクチン、トキソイドワクチン、組換えワクチン] ( Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023 / PH-6528) 販売に関する免責事項
[ワクチンの世界市場予測(~2023年):生ワクチン、トキソイドワクチン、組換えワクチン] ( Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023 / PH-6528) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆